Das Gehirn ist eine Goldmine

Beiträge: 9
Zugriffe: 482 / Heute: 1
geldschneider:

Das Gehirn ist eine Goldmine

 
10.08.04 13:10

für Biotech und Pharmazie Gesellschaften

s. auch Prana Biotech:

 http://www.ariva.de/board/193617/...;927&jump=1603741#jump1603741

 
E-mail | Print | Comments | License Reprints | E-Mail Newsletters | RSS Das Gehirn ist eine Goldmine 1603755
');//-->');   document.write('the best of life');   document.write('');   document.write('Das Gehirn ist eine Goldmine 1603755');   document.write('
 
');}else if( url.indexOf("/feeds/ap/") != -1 ) {   document.write('');   document.write('');   document.write('');   document.write('');   document.write('
Das Gehirn ist eine Goldmine 1603755
');}else if( url.indexOf("/feeds/businesswire/") != -1 ) {   document.write('');   document.write('');   document.write('');   document.write('');   document.write('
Das Gehirn ist eine Goldmine 1603755
');}else if( url.indexOf("/feeds/prnewswire/") != -1 ) {   document.write('');   document.write('');   document.write('');   document.write('');   document.write('
Das Gehirn ist eine Goldmine 1603755
');}else if( url.indexOf("/wireless/") != -1 ) {   document.write('');   document.write('');   document.write('');   document.write('');   document.write('
Das Gehirn ist eine Goldmine 1603755
');}//-->Pharmaceuticals
Neurological Drugs To Watch
Matthew Herper and Robert Langreth, 08.04.04, 12:00 PM ET

NEW YORK - The brain is a gold mine for drug companies. After all, some 20 million Americans suffer from depression alone. Our watch list of neurological drugs highlights the most promising experimental drugs to treat diseases of the brain and nervous system. Click on the drug names in the table below for more information, including sales forecasts and novelty ratings. Bookmark this page as it will be updated often.

Drug Maker Treats Development Stage
Antegren
(updated)
Biogen Idec (nasdaq: BIIB - news - people ), Elan (nyse: ELN - news - people ) Multiple sclerosis Awaiting regulatory decision
Cerovive Renovis (nasdaq: RNVS - news - people ), AstraZeneca (nyse: AZN - news - people ) Stroke Late-stage trial
Clioquinol Prana Biotechnology (nasdaq: PRAN - news - people ) Alzheimer's disease Mid-stage trial
Dexanabinol
(new)
Pharmos (nasdaq: PARS - news - people ) Traumatic brain injury Late-stage trial
Estorra Sepracor (nasdaq: SEPR - news - people ) Sleeplessness Awaiting regulatory decision
Gaboxadol Merck (nyse: MRK - news - people ), Lundbeck Sleeplessness Late-stage trial
Indiplon Neurocrine Biosciences (nasdaq: NBIX - news - people ), Pfizer (nyse: PFE - news - people ) Sleeplessness Late-stage trial
Lyrica Pfizer Epilepsy, neuropathic pain, anxiety Awaiting regulatory decision
Varenicline Pfizer Smoking addiction Late-stage trial

Sales ratings based on analyst reports and editor judgment. Novelty ratings based on editor judgment.

.box {border: 1px solid #000000;}.navtext {padding-bottom:2pt; padding-left:5pt; padding-top:4pt;}
Das Gehirn ist eine Goldmine 1603755
$ = up to $500 million in annual sales
$$ = $500 million to $1 billion
$$$ = $1 billion to $2 billion
$$$$ = more than $2 billion

+ = new drug in existing class
++ = significant advance over existing therapies
+++ = new class of medicines, or dramatic improvement
++++ = potential new paradigm

geldschneider:

Krebs Wirkstoffe auf der Watch!

 
10.08.04 14:00
Pharmaceuticals
Cancer Drugs To Watch
Matthew Herper and Robert Langreth, 07.15.04, 4:10 PM ET

NEW YORK - The race is on for new medicines to fight cancer. Here is a watch list of the most promising experimental drugs. Click on the drug names in the table below for more information, including sales forecasts and novelty ratings. Bookmark this page as it will be updated often.

Drug Maker First Indication Development Stage
572016 GlaxoSmithKline (nyse: GSK - news - people ) Breast cancer, bladder cancer Late-stage trial
ABX-EGF
(updated)
Abgenix (nasdaq: ABGX - news - people ), Amgen (nasdaq: AMGN - news - people ) Colon cancer, other tumors Late-stage trial
BAY-43-9006
(updated)
Onyx Pharmaceuticals (nasdaq: ONXX - news - people ), Bayer (nyse: BAY - news - people ) Advanced kidney cancer Late-stage trial
PTK-787 Novartis (nyse: NVS - news - people ) Colon cancer Late-stage trial
Provenge Dendreon (nasdaq: DNDN - news - people ) Prostate cancer Late-stage trial
Revlimid Celgene (nasdaq: CELG - news - people ) Myelodysplastic syndromes Late-stage trial
SU11248
(updated)
Pfizer (nyse: PFE - news - people ) Stomach cancer Late-stage trial
Tarceva
(updated)
OSI Pharmaceuticals (nasdaq: OSIP - news - people ), Genentech (nyse: DNA - news - people ), Roche (otc: RHHBY - news - people ) Lung cancer Late-stage trial
Telcyta
(updated)
Telik (nasdaq: TELK - news - people ) Ovarian cancer Late-stage trial

Sales ratings based on analyst reports and editor judgment. Novelty ratings based on editor judgment.

.box {border: 1px solid #000000;}.navtext {padding-bottom:2pt; padding-left:5pt; padding-top:4pt;}
Das Gehirn ist eine Goldmine 1603836
$ = up to $500 million in annual sales
$$ = $500 million to $1 billion
$$$ = $1 billion to $2 billion
$$$$ = more than $2 billion

+ = new drug in existing class
++ = significant advance over existing therapies
+++ = new class of medicines, or dramatic improvement
++++ = potential new paradigm


Das Gehirn ist eine Goldmine 1603836
1 of 10
Next >

geldschneider:

Other Drugs to watch!

 
10.08.04 14:05
Pharmaceuticals
Other Drugs To Watch
Matthew Herper and Robert Langreth, 05.03.04, 10:45 AM ET

NEW YORK - Sometimes, even drugmakers aren't running in packs. Here is a watch list of promising experimental drugs that didn't fit in our other groupings. Click on the drug names in the table below for more information, including sales forecasts and novelty ratings. Bookmark this page as it will be updated often.

Drug Maker Purpose Development Stage
AMG 162
(new)
Amgen (nasdaq: AMGN - news - people ) Treats osteoporosis Entering late-stage trial
Dalbavancin
(new)
Vicuron Pharmaceuticals (nasdaq: MICU - news - people ) Treats bacterial infections Late-stage trial
HPV vaccine Merck (nyse: MRK - news - people ) Treats human papilloma virus/cervical cancer Late-stage trial
Lucentis Genentech (nyse: DNA - news - people ), Novartis (nyse: NVS - news - people ) Treats macular degeneration Late-stage trial
Prexige Novartis Treats arthritis pain Late-stage trial

Sales ratings based on analyst reports and editor judgment. Novelty ratings based on editor judgment.

.box {border: 1px solid #000000;}.navtext {padding-bottom:2pt; padding-left:5pt; padding-top:4pt;}
Das Gehirn ist eine Goldmine 1603846
$ = up to $500 million in annual sales
$$ = $500 million to $1 billion
$$$ = $1 billion to $2 billion
$$$$ = more than $2 billion

+ = new drug in existing class
++ = significant advance over existing therapies
+++ = new class of medicines, or dramatic improvement
++++ = potential new paradigm


http://www.forbes.com/2004/01/26/cx_mh_rl_otherdrugtear.html
geldschneider:

Neue Antidepressiva

 
10.08.04 14:14
Lilly's re-entry into the antidepressant market won't be a cinch. Prozac is now off-patent and is not a significant source of revenue for the drugmaker. In its wake, similar drugs hit the market from Pfizer (nyse: PFE - news - people ), GlaxoSmithKline (nyse: GSK - news - people ) and Forest Laboratories (nyse: FRX - news - people ). Of special importance to Lilly will Effexor, from Wyeth (nyse: WYE - news - people ). Like Cymbalta, Effexor works by preventing the brain from reabsorbing the neurotransmitters serotonin and norepinephrine. Medicines such as Prozac and Forest's Celexa work only on serotonin.

To market its medicine in a crowded field, Lilly is emphasizing that Cymbalta helps not only with the mental symptoms of depression but also with physical aches and pains that often accompany the disease. Some 19 million Americans are thought to struggle with depression in any given year. Lilly, known for having one of the best new drug pipelines in the pharmaceutical industry, has also had cancer drug Alimta and erectile dysfunction treatment Cialis approved within the past 12 months.


Nussriegel:

hmmm, mit Antidepresiva Geld machen

 
10.08.04 19:11
wenn´s sein muss.
Du hattest doch mal lekkere Joghurt- und Schokoladen-Aktien vorgestellt.
was ist denn mit denen?
Oder Öko-Zeugs.
Halt irgendwas, was Freude macht...
gruß,
Nussriegel
Karl_S:

Tumorforschung

 
10.08.04 21:35

hastu du schonmal einen Blick auf Perigrine Pharmaceuticals (PPHM) geworfen? Zum Thema Gehirn und Goldmiene passt die ganz gut.

Grüsse,Karl
www.aktienboard.com

 

Nussriegel:

Peregrine Pharm ?

 
11.08.04 14:11
Wolltest du die Aktie empfehlen oder sagen,. dass das mit der Goldmiene m´nicht so ist, Karl_S?

Stock Analysis of Peregrine Pharm as of 8/10/2004

 
Analysis Summary
PPHM is overvalued compared to its Price of $1.08 per share, has somewhat below average safety, and is currently rated a Sell.
 
In-Depth Analysis
Business: PEREGRINE PHARMACEUTICLS INC, (PPHM) researches, develops and commercializes cancer therapeutics and cancer diagnostics. The company's main focus is on the development of its collateral targeting agent technologies which typically use antibodies that bind to or target stable structures
 
Price: PPHM closed on 8/10/2004 at $1.08 per share  
 
Value: Value is a measure of a stock's current worth.  PPHM has a current Value of $0.09 per share. Therefore, it is overvalued compared to its Price of $1.08 per share.  
 
RV (Relative Value): RV is an indicator of long-term price appreciation potential. PPHM has an RV of 0.07, which is very poor on a scale of 0.00 to 2.00.
RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00.
 
RS (Relative Safety): RS is an indicator of risk. PPHM has an RS rating of 0.81, which is poor on a scale of 0.00 to 2.00. RS is computed from an analysis of the consistency and predictability of a company's financial performance, debt to equity ratio, sales volume, business longevity, price volatility and other factors.

 

RT (Relative Timing): RT is a fast, smart, accurate indicator of a stock's price trend. PPHM has a Relative Timing rating of 0.56, which is poor on a scale of 0.00 to 2.00.  RT is computed from an analysis of the direction, magnitude, and dynamics of a stock's price movements over one day, one week, one quarter and one year time periods.

 
VST (VST-Vector):  VST is the master indicator for ranking every stock in the VectorVest database. PPHM has a VST rating of 0.58, which is poor on a scale of 0.00 to 2.00. VST is computed from the square root of a weighted sum of the squares of RV, RS, and RT. Stocks with the highest VST ratings have the best combinations of Value, Safety and Timing. These are the stocks to own for above average, long-term capital appreciation. VectorVest advocates the purchase of safe, undervalued stocks rising in price.  
 
CI (Comfort Index): CI is an indicator which reflects a stock's ability to resist severe and/or lengthy price declines. PPHM has a CI rating of 0.09, which is very poor on a scale of 0.00 to 2.00. CI is quite different from RS in that it is based solely upon a stock's long-term price history.
 
GRT (Earnings Growth Rate): GRT reflects a company's one to three year forecasted earnings growth rate in percent per year. PPHM has a forcasted Earnings Growth Rate of -7.00%, which we consider to be very poor. GRT is computed from historical, current and forecasted earnings data. It is updated each week for every stock in the VectorVest database. GRT often foretells a stock's future price trend. If a stock's GRT trend is upward, the stock's price will likely rise. If GRT is trending downward, the stock's Price will probably fall.
geldschneider:

@karl, bin auch nicht recht schlau geworden, was

 
12.08.04 13:14
die genau machen! PPHM

Kannst du uns das bitte kurz zusammenfassen? danke.

gs


Zu beobachten lohnt sich jedenfalls die jeweils Top Ten von Forbes s.#1 und ff

Karl_S:

pphm

 
12.08.04 17:26
ist als klassisches Biotechunternehmen im Bereich der Medikamentenentwicklung, insbesondere der Hirntumorforschung, tätig. Hier mal ein Auszug für den Sektor, den ich für am aussichtsreichsten halte (aus ihrem Mai-NL):Tumor Necrosis Therapy (TNT)We are continuing the clinical development efforts for our lead TNT program CotaraT.  We are currently treating patients in a phase I colorectal cancer trial being run at Stanford University Medical Center.This CotaraT phase I clinical trial is designed to evaluate the safety and radiation dosimetry of a single intravenous administration of the drug by treating groups of three patients (a cohort) and following those patients for eight weeks to monitor side effects before escalating the dose and treating the next cohort of patients.  Once the maximum tolerated dose for CotaraT has been reached and verified, the company should be in a position to initiate additional safety and efficacy studies in various other solid tumor types, including lung cancer. We expect to complete the current Stanford study by the end of calendar 2004 or by early 2005.Additional clinical studies in a number of solid tumor types are an important step toward expanding the commercial potential of CotaraT.Given the broad targeting nature of the TNT targeting platform, we believe that the technology will have broad applicability for the treatment of many tumor types.  Evidence of the potential for CotaraT was illustrated this year with positive results reported for TNT based compounds.  A TNT compound developed in China by MediPharm received marketing approval for the treatment of lung cancer. The rights to this compound were obtained from Peregrine under a licensing agreement with Cancer Therapeutics, Inc.Highlights of the data provided by MediPharm included a 34% overall response rate and an 87% disease control rate (stable disease plus overall response rate).  In clinical data published this year from a phase I clinical trial at the Mayo Clinic, CotaraT demonstrated excellent potential to be an effective combination therapy with radiofrequency ablation.We have approval from the FDA to initiate a product registration trial for advanced brain cancer. The trial has been postponed until we have a development partner or grant support for the program. Commencing the CotaraT brain cancer registration study remains a high priority for Peregrine. While we continue to look for a partner and or seek other sources of funding, we believe that treating other solid tumor types, such as lung cancer, should increase the commercial potential of the product.In addition to the promising results with radiolabeled TNT antibodies, data was published and presented this year indicating the potential of TNT antibodies to deliver cytokines and diagnostic agents for the treatment and diagnosis of cancer. TNT targeted cytokines are being developed by Merck KGaA under a license from Peregrine.@nussriegel: woher stammte deine Analyse?cheers, Karlwww.aktienboard.com
Es gibt keine neuen Beiträge.


Börsen-Forum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen
--button_text--